This document is a Quarterly Report (Form 10-Q) filed by Amgen Inc. with the U.S. Securities and Exchange Commission, providing a comprehensive overview of the company's financial performance for the three and six months ended June 30, 2025. It includes condensed consolidated financial statements (income, comprehensive income, balance sheets, cash flows), notes to those statements, and management's discussion and analysis of the company's financial condition and results of operations. The report details product sales, operating expenses, tax matters, investment portfolio information, and outlines legal proceedings, contingencies, and risks such as those related to government pricing policies and global economic conditions, fulfilling regulatory disclosure requirements.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related